New Drug Boosts Survival in Prostate Ca

November 21, 2013 8:24 PM

21 0

Men with advanced prostate cancer gained an extra 3 months of life with an investigational immunomodulator, including a 7-month survival improvement in patients with bone metastases, a randomized trial showed.

Treatment with tasquinimod was associated with a median overall survival of 33 months compared with 30 months in placebo-treated patients. The rate of disease progression slowed by almost 50% in men treated with tasquinimod. The difference in overall survival achieved statistical significance only i...

Read more

To category page